Innovative cancer immunotherapy, anti-PD-1 antibody Nivolumab

被引：0
|
作者：
Shibayama, Shiro [1 ]
机构：
[1] ONO Pharm, Res Cent Immunol, Osaka, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2017年 / 133卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
1-CS-01-1
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [21] Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
    Matias, M.
    Aspeslagh, S.
    Palomar, V.
    Lanoy, E.
    Dercle, L.
    Even, C.
    Ferte, C.
    Hollebecque, A.
    Marabelle, A.
    Massard, C.
    Soria, J-C.
    Postel-Vinay, S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [22] Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab
    Hamanishi, J.
    Mandai, M.
    Matsumura, N.
    Abiko, K.
    Baba, T.
    Yamaguchi, K.
    Konishi, I.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 137 : 23 - 23
  • [23] Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress
    Torrente-Lopez, Anabel
    Hermosilla, Jesus
    Salmeron-Garcia, Antonio
    Cabeza, Jose
    Navas, Natalia
    [J]. PHARMACEUTICS, 2022, 14 (04)
  • [24] Toxicities of the anti-PD-1 immune checkpoint antibody nivolumab in the acute inpatient setting.
    Brito-Dellan, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26)
  • [25] ANTI-PD-1 AND ANTI-PD-L1 ANTIBODIES AS IMMUNOTHERAPY AGAINST CANCER: A STRUCTURAL PERSPECTIVE
    Cordova-Bahena, Luis
    Velasco-Velazquez, Marco A.
    [J]. REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2021, 73 (01): : 8 - 16
  • [26] Durable remission with nivolumab, anti-PD-1 monoclonal antibody, in a patient with advanced thymic carcinoma
    Chae, Young Kwang
    Cho, Anderson
    Rhee, Kyunghoon
    Davis, Andrew
    Iams, Wade
    Bhave, Manali
    Cruz, Marcelo
    Park, Lee Chun
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [27] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shibata
    Yosuke Tamura
    Yoshitaka Seki
    Kazunori Honda
    Yuko Tanabe
    Hiroshi Wakui
    Tomohide Tamura
    [J]. Investigational New Drugs, 2017, 35 : 207 - 216
  • [28] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shibata, Takashi
    Tamura, Yosuke
    Seki, Yoshitaka
    Honda, Kazunori
    Tanabe, Yuko
    Wakui, Hiroshi
    Tamura, Tomohide
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 207 - 216
  • [29] A Case of Acute Myocarditis During Treatment With Anti-PD-1 Antibody Nivolumab in a Melanoma Patient
    Tadokoro, Tomonori
    Keshino, Eri
    Mohri, Masahiro
    [J]. JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S220 - S220
  • [30] Anti-PD-1 antibody treatment for melanoma
    Ribas, Antoni
    Kirkwood, John M.
    Flaherty, Keith T.
    [J]. LANCET ONCOLOGY, 2018, 19 (05): : E219 - E219
12345